Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPerkhofer, Lukas
dc.contributor.authorGolan, Talia
dc.contributor.authorCuyle, Pieter-Jan
dc.contributor.authorMatysiak-Budnik, Tamara
dc.contributor.authorVan Laethem, Jean-Luc
dc.contributor.authorMacarulla Mercadé, Teresa
dc.date.accessioned2022-05-11T08:29:15Z
dc.date.available2022-05-11T08:29:15Z
dc.date.issued2021-08-24
dc.identifier.citationPerkhofer L, Golan T, Cuyle PJ, Matysiak-Budnik T, Laethem JL Van, Macarulla T, et al. Targeting DNA Damage Repair Mechanisms in Pancreas Cancer. Cancers 2021. 2021 Aug 24;13(17):4259.
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/11351/7506
dc.descriptionBRCA1/2; PARP inhibition; Pancreatic ductal adenocarcinoma
dc.description.abstractImpaired DNA damage repair (DDR) is increasingly recognised as a hallmark in pancreatic ductal adenocarcinoma (PDAC). It is estimated that around 14% of human PDACs harbour mutations in genes involved in DDR, including, amongst others, BRCA1/2, PALB2, ATM, MSH2, MSH6 and MLH1. Recently, DDR intervention by PARP inhibitor therapy has demonstrated effectiveness in germline BRCA1/2-mutated PDAC. Extending this outcome to the significant proportion of human PDACs with somatic or germline mutations in DDR genes beyond BRCA1/2 might be beneficial, but there is a lack of data, and consequently, no clear recommendations are provided in the field. Therefore, an expert panel was invited by the European Society of Digestive Oncology (ESDO) to assess the current knowledge and significance of DDR as a target in PDAC treatment. The aim of this virtual, international expert meeting was to elaborate a set of consensus recommendations on testing, diagnosis and treatment of PDAC patients with alterations in DDR pathways. Ahead of the meeting, experts completed a 27-question survey evaluating the key issues. The final recommendations herein should aid in facilitating clinical practice decisions on the management of DDR-deficient PDAC.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;13(17)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectPàncrees - Càncer - Prognosi
dc.subjectADN - Reparació
dc.subject.meshPancreatic Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshDNA Repair
dc.subject.meshPrognosis
dc.titleTargeting DNA Damage Repair Mechanisms in Pancreas Cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers13174259
dc.subject.decsneoplasias pancreáticas
dc.subject.decs/farmacoterapia
dc.subject.decsreparación del ADN
dc.subject.decspronóstico
dc.relation.publishversionhttps://doi.org/10.3390/cancers13174259
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Perkhofer L] Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany. [Golan T] Oncology Institute, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel. [Cuyle PJ] Digestive Oncology Department, Imelda General Hospital, Bonheiden, Belgium. University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium. [Matysiak-Budnik T] IMAD, Department of Gastroenterology and Digestive Oncology, Hôtel Dieu, CHU de Nantes, Nantes, France. [Van Laethem JL] GI Cancer Unit, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. [Macarulla T] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid34503069
dc.identifier.wos000694122200001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record